Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy. (2018)
Attributed to:
The University of Manchester (UoM) bid for phase III of MRC Confidence in Concept funding
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/jca.21599
PubMed Identifier: 29094388
Publication URI: http://europepmc.org/abstract/MED/29094388
Type: Journal Article/Review
Volume: 33
Parent Publication: Journal of clinical apheresis
Issue: 3
ISSN: 0733-2459